Autologous Cord Blood

Summary

Autologous Cord Blood (CHEMBL4594461) is a phase-3 clinical-stage unknown; indicated across 10 conditions including bronchopulmonary dysplasia and brain ischemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 10 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594461
Name	Autologous Cord Blood
Type	Unknown
Max phase	3

Also known as: Autologous cord blood, Autologous human umbilical cord blood, Autologous umbilical cord blood, AUTOLOGOUS CORD BLOOD

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bronchopulmonary dysplasia	3	MONDO:0019091	MONDO:0019091
brain ischemia	2	MONDO:0005299	MONDO:0005299
autism	2	MONDO:0005260	EFO:0003758
cerebral palsy	2	MONDO:0006497	EFO:1000632
autism spectrum disorder	1	MONDO:0005258	EFO:0003756
hearing loss disorder	1	MONDO:0005365	EFO:0004238
congenital diaphragmatic hernia	1	MONDO:0005711	EFO:0007216
brain injury	1	MONDO:0043510	MONDO:0043510
hypoplastic left heart syndrome	1	MONDO:0004933	MONDO:0004933

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE1	8
PHASE1/PHASE2	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01251003	PHASE1/PHASE2	WITHDRAWN	Safety Study of Umbilical Cord Blood To Treat Pediatric Traumatic Brain Injury
NCT02551003	PHASE1/PHASE2	WITHDRAWN	Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
NCT04243382	PHASE2	UNKNOWN	Treatment of Children With Autistic Spectrum Disorder With Autologous Umbilical Cord Blood, a Pilot Study
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01445041	PHASE1	TERMINATED	Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome
NCT01649648	PHASE1	COMPLETED	Autologous Cord Blood Cells for Brain Injury in Term Newborns
NCT02176317	PHASE1	COMPLETED	Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)
NCT03526588	PHASE1	TERMINATED	Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)
NCT03791372	PHASE1	UNKNOWN	Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
NCT04007224	PHASE1	COMPLETED	Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder
NCT04768816	PHASE1	UNKNOWN	Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Autism Spectrum Disorder

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).